Our Clinical Studies


Clinical Pipeline

Our current clinical studies build on the progress we’ve made to validate the first prognostic test for inflammatory bowel disease.  The PROFILE and PRECIOUS studies extend the validation and clinical utility of PredictSURE® IBD, respectively.

About the


The PROFILE study is the first biomarker stratified study for inflammatory bowel disease, supported by £4.3M finance from Wellcome Trust, PROFILE seeks to explore whether targeting therapy changes outcomes in biomarker-defined subgroups of patients with newly diagnosed Crohn’s disease (CD).  The study is designed to recruit 400 CD patients from 40 sites around the UK.

About the


The PRECIOUS study is an observational study designed to recruit 200 newly diagnosed IBD patients across multiple sites. This will extend our UK based validation cohort to the US population to further validate the biomarker.  The study is supported by the Crohn’s & Colitis Foundation.